131 related articles for article (PubMed ID: 35699966)
21. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
[TBL] [Abstract][Full Text] [Related]
22. Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation.
Freyer CW; Carulli A; Ganetsky A; Hughes ME; Krause TM; Timlin C; Frey NV; Gill SI; Hexner EO; Loren AW; Mangan JK; Martin ME; McCurdy SR; Perl AE; Pratz K; Porter DL; Luger SM
Leuk Lymphoma; 2020 Sep; 61(9):2200-2207. PubMed ID: 32482107
[TBL] [Abstract][Full Text] [Related]
23. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
[TBL] [Abstract][Full Text] [Related]
24. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
25. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin.
Elliott MA; Wolf RC; Hook CC; Pruthi RK; Heit JA; Letendre LL; Tefferi A; Kaufmann SH; Mesa RA; Litzow MR
Leuk Lymphoma; 2004 Aug; 45(8):1545-9. PubMed ID: 15370205
[TBL] [Abstract][Full Text] [Related]
26. Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase.
Mark C; Gupta S; Punnett A; Upton J; Orkin J; Atkinson A; Clarke L; Heisey A; McGovern C; Alexander S
Pediatr Blood Cancer; 2021 Nov; 68(11):e29295. PubMed ID: 34398511
[TBL] [Abstract][Full Text] [Related]
27. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
28. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study.
Orvain C; Balsat M; Tavernier E; Marolleau JP; Pabst T; Chevallier P; de Gunzburg N; Cacheux V; Huguet F; Chantepie S; Caillot D; Chalandon Y; Frayfer J; Bonmati C; Lheritier V; Ifrah N; Dombret H; Boissel N; Hunault-Berger M
Blood; 2020 Jul; 136(3):328-338. PubMed ID: 32321172
[TBL] [Abstract][Full Text] [Related]
29. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
30. Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
Chen R; Liu X; Law AD; Kanfar S; Maze D; Chan SM; Gupta V; Yee KW; Minden MD; Schimmer AD; Schuh AC; McNamara CJ; Murphy T; Xu A; Falcone U; Seki J; Sibai H
Curr Oncol; 2020 Dec; 28(1):128-137. PubMed ID: 33704181
[TBL] [Abstract][Full Text] [Related]
31. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
[TBL] [Abstract][Full Text] [Related]
32. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study.
Athale UH; Laverdiere C; Nayiager T; Delva YL; Foster G; Thabane L; Chan AK
BMC Cancer; 2017 May; 17(1):313. PubMed ID: 28472942
[TBL] [Abstract][Full Text] [Related]
33. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.
Grace RF; DeAngelo DJ; Stevenson KE; Neuberg D; Sallan SE; Mourad YRA; Bergeron J; Seftel MD; Kokulis C; Connors JM
J Thromb Thrombolysis; 2018 Feb; 45(2):306-314. PubMed ID: 29260426
[TBL] [Abstract][Full Text] [Related]
34. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.
Grace RF; Dahlberg SE; Neuberg D; Sallan SE; Connors JM; Neufeld EJ; Deangelo DJ; Silverman LB
Br J Haematol; 2011 Feb; 152(4):452-9. PubMed ID: 21210774
[TBL] [Abstract][Full Text] [Related]
35. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.
Schulte R; Hinson A; Huynh V; Breese EH; Pierro J; Rotz S; Mixon BA; McNeer JL; Burke MJ; Orgel E
Cancer Med; 2021 Nov; 10(21):7551-7560. PubMed ID: 34528411
[TBL] [Abstract][Full Text] [Related]
36. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
[TBL] [Abstract][Full Text] [Related]
37. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Bade NA; Lu C; Patzke CL; Baer MR; Duong VH; Law JY; Lee ST; Sausville EA; Zimrin AB; Duffy AP; Lawson J; Emadi A
J Oncol Pharm Pract; 2020 Jan; 26(1):74-92. PubMed ID: 30917738
[TBL] [Abstract][Full Text] [Related]
38. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
[TBL] [Abstract][Full Text] [Related]
39. Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.
Silva WFD; Massaut IHB; Bendlin RM; Rosa LI; Velloso EDRP; Rego EM; Rocha V
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e523-e528. PubMed ID: 32389674
[TBL] [Abstract][Full Text] [Related]
40. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH
Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
